Vascepa sparkle set to light up Amarin's fourth quarter revenue
Basking in the glow of its keenly anticipated FDA approval for its fish oil pill in the blockbuster indication of reducing cardiovascular risk in patients already on statins, Amarin on Tuesday unveiled its preliminary fourth-quarter revenue that beat Wall Street estimates.
Amarin expects its total 2019 revenue to come in at, or slightly exceed, the upper end of its previously declared guidance of $410 million to $425 million, driven by the sales of its flagship drug, Vascepa. That works out to roughly $140 million for the fourth quarter, north of the consensus projection of $131 million and Jefferies’ estimate of $135 million, Jefferies analysts wrote in a note.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.